SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Mallinckrodt plc MNK NYSE

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • IE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Mallinckrodt plc (MNK) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.34. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Financials: revenue is $2.0B, -3.5%/yr average growth. Net income is $478M, growing at +64.3%/yr. Net profit margin is 24.1% (strong). Gross margin is 41.8% (+11.6 pp trend).

Balance sheet: total debt is $913M against $1.6B equity (Debt-to-Equity (D/E) ratio 0.55, moderate). Current ratio is 3.78 (strong liquidity). Debt-to-assets is 27.7%. Total assets: $3.3B.

Analyst outlook: 7 / 33 analysts rate MNK as buy (21%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 50/100 (Partial), Moat 55/100 (Partial), Future 20/100 (Fail), Income 85/100 (Pass).

MNK SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 55/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 85/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MNK

MNK trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MNK: -3.5%/yr revenue is, +64.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

MNK: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet MNK: Debt-to-Equity (D/E) ratio 0.55 (moderate), Current ratio is 3.78 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MNK: Gross margin is 41.8% (+11.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 55/100. ≥ 70 = Pass.

View details →

Analyst outlook: 7 / 33 analysts rate MNK as buy (21%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

MNK: Net profit margin is 24.1%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.3-16.0

Volume543.15K

Avg Volume (30D)3.71M

Market Cap$4.52M

Beta (1Y)0.00

Share Statistics

EPS (TTM)24.26

Shares Outstanding$19.7M

IPO Date2022-06-21

Employees2,673

CEOSigurdur Oli Olafsson

Financial Highlights & Ratios

Revenue (TTM)$1.98B

Gross Profit$827.1M

EBITDA$90.2M

Net Income$477.9M

Operating Income$90.2M

Total Cash$382.6M

Total Debt$913.4M

Net Debt$530.8M

Total Assets$3.3B

Price / Earnings (P/E)0

Price / Sales (P/S)0

Analyst Forecast

Rating ConsensusHold

Analysts Covering33

Buy 21% Hold 64% Sell 15%

Company Info

CountryIE

ExchangeNYSE

CurrencyUSD

Price Chart

MNK

Mallinckrodt plc ↗ · NYSE

Healthcare • Drug Manufacturers - Specialty & Generic

0.30 52WK RANGE 16.00

People Also View

Cronos Group Inc.

Canopy Growth Corporation

Organogenesis Holdings Inc.

Alimera Sciences, Inc.

Aurora Cannabis Inc.

Lifecore Biomedical, Inc.

Journey Medical Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message